Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P1) and 5 (S1P5)
modulator approved in the United States and the European Union as an oral treatment for …

Introduction: Multiple sclerosis (MS) causes focal lesions of immune-mediated
demyelinating events followed by slow progressive accumulation of disability. Over the past …

Siponimod (BAF312) is a synthetic molecule belonging to the sphingosine-1-phosphate
(S1P) modulator family, which has putative neuroprotective properties and well …

The modulation of the sphingosine 1-phosphate receptor is an approved treatment for
relapsing multiple sclerosis because of its anti-inflammatory effect of retaining lymphocytes …

Oral siponimod (Mayzent®), a next-generation, selective sphingosine 1-phosphate receptor
(S1PR) 1 and 5 modulator, is approved in several countries for the treatment of secondary …

Background Siponimod (BAF312), a selective S1P1/S1P5 agonist, reduces disability
progression in secondary progressive MS. Recent observations suggest it could act via …

Background Siponimod is a sphingosine 1-phosphate receptor modulator approved for
active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase …

Introduction: Multiple sclerosis (MS) is a chronic central nervous system immune-mediated
disease with an important inflammatory component associated with focal demyelination and …

Background Siponimod is an oral selective modulator of sphingosine 1-phosphate receptor
types 1 and type 5, with an elimination half-life leading to washout in 7 days. We aimed to …

Introduction Multiple sclerosis (MS) is an immune-mediated disorder of the CNS manifested
by recurrent attacks of neurological symptoms (related to focal inflammation) and gradual …